Navitoclax targets BCL-2 and BCL-XL and has been widely examined in combination with other therapies in numerous solid tumors, including rhabdomyosarcoma, small cell lung cancer, and endometrial carcinoma, and in hematologic malignancies including AML and ALL [38]. The gene discussed is BCL2L1; the disease is acute lymphoblastic leukemia.